Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pharmacia, Pfizer deal

PFE will acquire PHA in a stock deal valued at $49.9 billion. The combined company is expected to have pro forma 2002 earnings of $11.9 billion on $47.9 billion in revenues, said PFE. The merged entity also will have up to 12 products with more than $1 billion

Read the full 488 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers